Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07675590 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects
A Phase 1 study, sponsored by TIXiMED.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT07675590 is a Phase 1 study that is actively recruiting participants, run by TIXiMED. The registered enrollment target is 18 participants.
The verdict
NCT07675590, a Phase 1 study, is actively recruiting participants, sponsored by TIXiMED.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Randomized, Placebo-controlled Study to determine the safety and tolerability of multiple oral doses of TIX100 administered daily for 28 days to otherwise healthy overweight/obese subjects.
Interventions
- DRUG Placebo
- DRUG TIX100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-06-22 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07675590
The ClinicalTrials.gov registry entry for NCT07675590 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TIXiMED, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07675590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07675590 about?
NCT07675590 is a clinical study titled "A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects". Randomized, Placebo-controlled Study to determine the safety and tolerability of multiple oral doses of TIX100 administered daily for 28 days to otherwise healthy overweight/obese subjects.
What is the current status of trial NCT07675590?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-06-22. Estimated completion is 2026-12.
What interventions are being tested in trial NCT07675590?
The interventions under investigation include: Placebo (DRUG), TIX100 (DRUG).
Who is sponsoring clinical trial NCT07675590?
This trial is sponsored by TIXiMED, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.